

Bioceres Crop Solutions reports softer Q3 FY2026 performance amid strategic reset and portfolio restructuring

13 May 2026 | News

Argentine agri-biotech major posts \$39.4 million revenue, widening net loss and marginal negative EBITDA as it streamlines operations, exits Pro Farm Group and sharpens focus on core climate-resilient agricultural solutions



Argentine agri-biotech major posts \$39.4 million revenue, widening net loss and marginal negative EBITDA as it streamlines operations, exits Pro Farm Group and sharpens focus on core climate-resilient agricultural solutions

In a quarter emblematic less of collapse than of corporate recalibration, Bioceres Crop Solutions has reported fiscal third-quarter 2026 revenues of \$39.4 million, accompanied by a net loss of \$10.0 million and a marginally negative Adjusted EBITDA of \$0.6 million, as the Argentine agricultural biotechnology firm navigates a complex transition marked by portfolio restructuring, competitive pressures, and internal consolidation.

The company's financial performance for the three months ended March 31, 2026 reflects a 23 per cent year-over-year decline in total revenues, driven primarily by softer demand conditions in its Crop Protection segment and an ongoing structural transition within its Seeds business. These headwinds were partially offset by a 15 per cent expansion in Crop Nutrition revenues, underscoring pockets of resilience within an otherwise uneven operational landscape.

Gross profit for the quarter stood at \$12.7 million, translating into a gross margin of 32 per cent, a compression attributed to lower topline performance and adverse product mix dynamics across business units. Crop Nutrition results were further impacted by a non-recurring inventory obsolescence adjustment linked to inoculant stock normalization, highlighting the residual volatility inherent in biological input categories.

Operating discipline, however, emerged as a countervailing force. Selling, general and administrative expenses declined by 16 per cent year-over-year, reflecting deliberate cost rationalisation and organisational streamlining initiatives. These measures signal an intensifying focus on efficiency as the company recalibrates its operational base following a period of strategic reorientation.

The quarter was also shaped decisively by the classification of the Pro Farm Group as discontinued operations following its foreclosure auction in January 2026. This development, alongside associated creditor disputes, has necessitated an ongoing process of liability management, including debt reprofiling and bond maturity extensions within Argentina's constrained financial environment.

Federico Trucco, Chief Executive Officer of Bioceres, characterised the period as one of structural transition and operational refocusing, emphasising efforts to simplify organisational architecture, optimise capital allocation, and strengthen working capital discipline. He underscored that while near-term performance remains pressured, the company is actively repositioning itself toward long-term resilience and sustainable value creation.

At a strategic level, management has initiated a comprehensive review of continuing operations, with an explicit focus on aligning resources with high-impact growth areas within its climate-resilient agricultural portfolio. This includes a renewed emphasis on cash generation, governance reinforcement, and portfolio rationalisation, as Bioceres seeks to stabilise its core business amid lingering uncertainty from prior restructuring actions.

Notably, profitability metrics were also affected by the absence of non-cash income recorded in the prior year, related to structural changes in Seeds and associated intellectual property arrangements, complicating direct year-over-year comparability.

Despite the financial headwinds, Crop Nutrition emerged as a relative growth engine, driven by microbial and microbeaded fertilizer solutions—an area increasingly aligned with global demand for regenerative agriculture inputs and reduced chemical dependency.

As Bioceres moves deeper into its strategic reset phase, the company's trajectory reflects a broader tension confronting agri-biotech firms globally: the challenge of balancing scientific ambition and climate-aligned innovation with the unforgiving arithmetic of cash flows, capital discipline, and cyclical agricultural demand.